Please assess the completion status of the following clinical trial:

Trial Title: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age 18 years or older~2. Histologically confirmed diagnosis of MZL including splenic, nodal, and extranodal subtypes~3. Previously received one or more lines of therapy including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least partial response or documented progressive disease (PD) after, the most recent systemic treatment~4. Current need for systemic therapy for MZL~5. Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)~6. Eastern Cooperative Oncology Group (ECOG) of 0-2~7. Life expectancy ≥ 6 months~8. Adequate bone marrow function~9. Adequate organ function~10. Male and female participants must use highly effective methods of contraception~Key Exclusion Criteria:~1. Known transformation to aggressive lymphoma, eg, large cell lymphoma~2. Clinically significant cardiovascular disease~3. Prior malignancy within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer~4. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention~5. History of stroke or intracranial hemorrhage~6. Severe or debilitating pulmonary disease~7. Active fungal, bacterial and/or viral infection requiring systemic therapy~8. Known central nervous system involvement by lymphoma~9. Known infection with HIV, or serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection~10. Major surgery within 4 weeks of the first dose of study drug~11. Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor~12. Pregnant or lactating women~13. Requires ongoing treatment with a strong Cytochrome P4503A (CYP3A) inhibitor or inducer~14. Concurrent participation in another therapeutic clinical trial~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib (Type: EXPERIMENTAL): Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).